BRMS1 Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-1015R-Cy7 |
| Product Name | BRMS1 Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human BRMS-1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 25855 |
| Swiss Prot | Q9HCU9 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | Breast cancer metastasis-suppressor 1; BRMS1 |
| Background | Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |